CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Elranatamab 在治疗伴中枢神经系统受累的难治性多发性骨髓瘤中的有效性
英文原题：The Effectiveness of Elranatamab in the Management of Refractory Multiple Myeloma with Central Nervous System Involvement.
查看英文原题
The Effectiveness of Elranatamab in the Management of Refractory Multiple Myeloma with Central Nervous System Involvement.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤伴中枢神经系统（CNS）受累较为罕见，且预后不良。尽管包括CAR-T 细胞疗法和双特异性抗体在内的新型疗法的出现使得多发性骨髓瘤获得长期疾病控制成为可能，但对于CNS受累病例，目前仍尚无确立的标准治疗方案，新型疗法的疗效仍不明确。据我们所知，本文报告了日本首例成功使用elranatamab治疗难治性多发性骨髓瘤伴CNS受累导致意识障碍患者的病例。
展开英文摘要原文
Multiple myeloma with central nervous system (CNS) involvement is rare and associated with a poor prognosis. Although the emergence of novel therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies, has made it possible to obtain long-term disease control in multiple myeloma, there is still no established standard treatment for cases with CNS involvement, and the efficacy of novel therapies remains unclear.
To our knowledge, we herein report the first case of successful elranatamab treatment in Japan in a patient with refractory multiple myeloma showing impaired consciousness caused by CNS involvement.
论文信息
- 作者
- Uemura M、Marumo A、Obata A、Matsumoto N、Li M、Kaito Y、Nagata Y、Wakita S
- 单位
- Department of Hematology, Nippon Medical School, Japan.Japan
- 文献类型
- 病例报告
- 期刊
- Internal medicine (Tokyo, Japan)2026 Aug 15
- 原文标识
- PubMed 41535029 · DOI 10.2169/internalmedicine.6418-25
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →